1. 2017 White Paper: rise of hybrid LBA/LCMS immunogenicity assays (Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies' inputs). (December 2017) Authors: Neubert, Hendrik; Song, An; Lee, Anita; Wei, Cong; Duggan, Jeff; Xu, Keyang; Woolf, Eric; Evans, Chris; Palandra, Joe; Laterza, Omar; Amur, Shashi; Berger, Isabella; Bustard, Mark; Cancilla, Mark; Chen, Shang-Chiung; Cho, Seongeun (Julia); Ciccimaro, Eugene; Cludts, Isabelle; Cocea, Laurent; D'Ar... Journal: Bioanalysis Issue: Volume 9:Number 23(2017) Page Start: 1895 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis. (16th May 2016) Authors: Gupta, Neeraj; Hanley, Michael J.; Harvey, R. Donald; Badros, Ashraf; Lipe, Brea; Kukreti, Vishal; Berdeja, Jesus; Yang, Huyuan; Hui, Ai‐Min; Qian, Mark; Zhang, Xiaoquan; Venkatakrishnan, Karthik; Chari, Ajai Journal: British journal of haematology Issue: Volume 174:Number 5(2016) Page Start: 748 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗